Potential THR-beta agonist may more safely, effectively treat MASH
Once daily treatment with oral ALG-055009 safely lowered levels of liver fat in people with metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty…
Lindsey Shapiro, PhD, Science Writer — 
Articles by Lindsey Shapiro
FDA committee votes 10-1 against Ocaliva’s full approval for PBC
A U.S. Food and Drug Administration (FDA) advisory committee voted 10-1 that Ocaliva (obeticholic acid) doesn’t have a benefit-risk profile that would support its…
American Liver Foundation gala to recognize biliary atresia family
The American Liver Foundation (ALF) is granting its Spirit of Giving Family Award to a U.S. family for its dedication to raising funds and…
Study offers insights into potential for vaccine for hepatitis C
Researchers have uncovered the structure of the protein complex that allows the hepatitis C virus (HCV) to infect human cells, allowing them to reproduce and…
Advanz gets suspension of decision to revoke Ocaliva EU approval
Advanz Pharma has secured a temporary suspension of a decision by the European Commission (EC) to revoke conditional approval of Ocaliva (obeticholic acid) for…
Nonprofit’s petition aims to expedite Canadian access to Rezdiffra
The Fatty Liver Alliance, a Canada-based advocacy group, is calling for supporters to sign a petition asking Madrigal Pharmaceuticals to apply to Canadian…
Study details antiviral mechanisms of Atea treatment for hepatitis C
Researchers have detailed exactly how bemnifosbuvir — part of Atea Pharmaceuticals’ antiviral treatment combination for chronic hepatitis C infections — turns into the…
Antiviral therapy eases hepatitis C, prevents complications: Study
Treatment with direct-acting antivirals (DAAs) reduces the disease burden associated with liver scarring (fibrosis) and prevents severe liver outcomes and death among people with chronic…
Antiviral treatment combo leads to sustained HCV clearance in trial
A two-month regimen of Atea Pharmaceuticals’ once-daily oral antiviral treatment for hepatitis C — a combination of bemnifosbuvir and ruzasvir — leads to sustained…
Researchers develop new way to recognize Alagille-causing mutations
A team of researchers has developed a new screening system to identify previously unrecognized mutations as the likely cause of Alagille syndrome. In a…
